The vaccine candidate, which has been licensed to AstraZeneca, has published interim late stage trial results showing higher efficacy when a half dose is followed by a full dose, compared to a two full-dose regime, though more work needs to be done to affirm the result.
from Hindustan Times - world https://ift.tt/3mt2wgr
No comments:
Post a Comment